Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: Detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)

Oncologist

Volumn 21, Issue 10, 2016, Pages 1165-1175

  Verma, Sunil ^a   Bartlett, Cynthia Huang ^b   Schnell, Patrick ^b   DeMichele, Angela M ^c   Loi, Sherene ^d   Ro, Jungsil ^e   Colleoni, Marco ^f   Iwata, Hiroji ^g   Harbeck, Nadia ^h   Cristofanilli, Massimo ⁱ   Zhang, Ke ^b   Thiele, Alexandra ^b   Turner, Nicholas C ^j   Rugo, Hope S ^k  

^a UNIVERSITY OF CALGARY   (Canada)

^b PFIZER INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e National Cancer Center   (South Korea)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Cyclin dependent kinase 4; Cyclin dependent kinase 6; Neutropenia; Palbociclib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; PALBOCICLIB; PLACEBO; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; FATIGUE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; STOMATITIS; TREATMENT OUTCOME; UPPER EXTREMITY DEEP VEIN THROMBOSIS; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; METASTASIS; MORTALITY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; NEOPLASM METASTASIS; PIPERAZINES; PYRIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84991660586     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0097     Document Type: Article

References (20)

1. Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014; 25:1871–1888.
2. Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA. Breast Cancer Res 2015;17:40.
3. Finn RS, Crown JP, Lang I et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA- 1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16:25–35.
4. Cristofanilli M, Turner NC, Bondarenko I et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptorpositive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425–439.
5. Turner NC, Ro J, André F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl JMed 2015;373:209–219.
6. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
7. US Department of Health and Human Services, National Institutes ofHealth,National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.2009. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed June 14, 2016.
8. Beaver JA, Park BH. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptorpositive advanced breast cancer. Future Oncol 2012;8:651–657.
9. Baselga J, Im SA, Iwata H et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR1/HER2– advanced breast cancer (BC): First results fromthe randomized, phase III BELLE-2 trial. Presented at: SanAntonio Breast Cancer Symposium; December 8–12, 2015; San Antonio, TX.
10. Harbeck N, Cristofanilli M, Ro J et al. Doubleblind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR1ve), HER2- negative (HER22ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes. Eur J Cancer 2015;51:S270–S271.
11. Hu W, Sung T, Jessen B et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res 2016;22: 2000–2008.
12. Tofts PS, Chevassut T, Cutajar M et al. Doubts concerning the recently reported human neutrophil lifespan of 5.4 days. Blood 2011;117:6050–6052; author reply 6053–6054.
13. Crawford J, Dale DC, Lyman GH. Chemotherapy induced neutropenia: Risks, consequences, and new directions for its management. Cancer 2004;100: 228–237.
14. Lyman GH. Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park) 2006; 20(suppl 9):16–25.
15. Roberts PJ, Bisi JE, Strum JC et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476–487.
16. Johnson SM, Torrice CD, Bell JF et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010;120:2528–2536.
17. Finn RS, Dering J, Conklin D et al. PD0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
18. Bhatt V, Saleem A. Review: Drug-induced neutropenia–pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004;34: 131–137.
19. Lalami Y, Paesmans M, Muanza F et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 2006;17:507–514.
20. ClinicalTrials.gov. Study comparing two different schedules of palbociclib plus second line endocrine therapy in womenwith estrogen receptor positive, HER2 negative advanced/metastatic breast cancer. 2016. Available at https://clinicaltrials.gov/ct2/show/NCT02630693. Accessed April 25, 2016.